# AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

> **NCT05302336** · PHASE4 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 402 (estimated)

## Conditions studied

- Breast Cancer
- Chemotherapeutic Toxicity

## Interventions

- **DRUG:** Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide

## Key facts

- **NCT ID:** NCT05302336
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05302336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05302336, "AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05302336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*